Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease.

Fishbane S, Spinowitz BS, Wisemandle WA, Martin NE.

Kidney Int Rep. 2019 May 22;4(9):1235-1247. doi: 10.1016/j.ekir.2019.05.010. eCollection 2019 Sep.

2.

Minimum Data Elements for Radiation Oncology: An American Society for Radiation Oncology Consensus Paper.

Hayman JA, Dekker A, Feng M, Keole SR, McNutt TR, Machtay M, Martin NE, Mayo CS, Pawlicki T, Smith BD, Kudner R, Dawes S, Yu JB.

Pract Radiat Oncol. 2019 Nov;9(6):395-401. doi: 10.1016/j.prro.2019.07.017. Epub 2019 Aug 21.

PMID:
31445187
3.

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level.

Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):941-948. doi: 10.6004/jnccn.2018.7283.

PMID:
31390585
4.

Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.

Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw KW, Nguyen PL, Muralidhar V.

Cancer. 2019 Sep 15;125(18):3164-3171. doi: 10.1002/cncr.32202. Epub 2019 May 31.

PMID:
31150125
5.

Now You're Speaking My Language: Getting Patient-reported Outcomes to Talk to One Another.

Martin NE.

Eur Urol. 2019 May;75(5):731-732. doi: 10.1016/j.eururo.2019.01.041. Epub 2019 Feb 5. No abstract available.

PMID:
30737075
6.

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL.

Eur Urol. 2019 Jan;75(1):35-41. doi: 10.1016/j.eururo.2018.08.033. Epub 2018 Oct 24.

PMID:
30554605
7.

An Ion-Permeable State of the Glycine Receptor Captured by Molecular Dynamics.

Cerdan AH, Martin NÉ, Cecchini M.

Structure. 2018 Nov 6;26(11):1555-1562.e4. doi: 10.1016/j.str.2018.07.019. Epub 2018 Sep 13.

8.

Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.

Fishbane S, Singh B, Kumbhat S, Wisemandle WA, Martin NE.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1204-1214. doi: 10.2215/CJN.11631017. Epub 2018 Jun 19.

9.

Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce.

Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Am J Med. 2018 May;131(5):517-523. doi: 10.1016/j.amjmed.2017.11.039. Epub 2018 Mar 16.

PMID:
29555248
10.

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL.

Eur Urol. 2018 Aug;74(2):146-154. doi: 10.1016/j.eururo.2018.01.043. Epub 2018 Feb 22.

11.

Impact of a clinical pathway tool on appropriate palliative radiation therapy for bone metastases.

Rotenstein LS, Kerman AO, Killoran J, Balboni TA, Krishnan MS, Taylor A, Martin NE.

Pract Radiat Oncol. 2018 Jul - Aug;8(4):266-274. doi: 10.1016/j.prro.2017.12.001. Epub 2017 Dec 8.

PMID:
29429920
12.

Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.

Kamran SC, Seisen T, Markt SC, Preston MA, Trinh QD, Frazier LA, Choueiri TK, Martin NE, Nguyen PL, Beard CJ.

Eur Urol. 2018 Apr;73(4):e96-e97. doi: 10.1016/j.eururo.2017.12.026. Epub 2018 Jan 19. No abstract available.

PMID:
29358058
13.

Travel distance and stereotactic body radiotherapy for localized prostate cancer.

Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF 3rd, Nguyen PL.

Cancer. 2018 Mar 15;124(6):1141-1149. doi: 10.1002/cncr.31190. Epub 2017 Dec 12.

14.

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.

Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF 3rd, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2018 Jun;16(3):226-234. doi: 10.1016/j.clgc.2017.10.013. Epub 2017 Nov 9.

PMID:
29196209
15.

Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.

Seisen T, Kamran SC, Markt SC, Preston MA, Trinh QD, Frazier LA, Choueiri TK, Martin NE, Nguyen PL, Beard CJ.

Eur Urol. 2018 Apr;73(4):e100-e101. doi: 10.1016/j.eururo.2017.10.013. Epub 2017 Nov 3. No abstract available.

PMID:
29108659
16.

Un-gating and allosteric modulation of a pentameric ligand-gated ion channel captured by molecular dynamics.

Martin NE, Malik S, Calimet N, Changeux JP, Cecchini M.

PLoS Comput Biol. 2017 Oct 25;13(10):e1005784. doi: 10.1371/journal.pcbi.1005784. eCollection 2017 Oct.

17.

Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.

Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF 3rd, King MT.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):904-911. doi: 10.1016/j.ijrobp.2017.07.034. Epub 2017 Jul 31.

PMID:
29063853
18.

Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy.

Yang DD, Muralidhar V, Mahal BA, Beard CJ, Mouw KW, Martin NE, Orio PF 3rd, King MT, Nguyen PL.

Am J Clin Oncol. 2018 Oct;41(10):953-959. doi: 10.1097/COC.0000000000000410.

PMID:
29045266
19.

Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.

Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, Bondi A, Lis R, Van Hemelrijck M, Andrén O, Andersson SO, Watson RW, Pennington S, Finn SP, Martin NE, Stampfer MJ, Parmigiani G, Penney KL, Fiorentino M, Mucci LA, Loda M.

Nat Commun. 2017 Sep 4;8(1):420. doi: 10.1038/s41467-017-00460-4.

20.

Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.

Yang DD, Mahal BA, Muralidhar V, Boldbaatar N, Labe SA, Nezolosky MD, Vastola ME, Beard CJ, Martin NE, Mouw KW, Orio PF 3rd, King MT, Nguyen PL.

Cancer. 2017 Dec 15;123(24):4832-4840. doi: 10.1002/cncr.30948. Epub 2017 Aug 22.

21.

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.

Eur Urol Focus. 2019 Jan;5(1):69-76. doi: 10.1016/j.euf.2017.05.011. Epub 2017 Jun 17.

PMID:
28753811
22.

Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience.

Kamran SC, Harshman LC, Bhagwat MS, Muralidhar V, Nguyen PL, Martin NE, La Follette S, Faso S, Viswanathan AN, Efstathiou JA, Beard CJ.

Adv Radiat Oncol. 2017 Jan 17;2(2):140-147. doi: 10.1016/j.adro.2017.01.001. eCollection 2017 Apr-Jun.

23.

Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer.

Kamran SC, Seisen T, Markt SC, Preston MA, Trinh QD, Frazier LA, Choueiri TK, Martin NE, Nguyen PL, Beard CJ.

Eur Urol. 2018 Feb;73(2):262-270. doi: 10.1016/j.eururo.2017.06.013. Epub 2017 Jul 4.

PMID:
28687143
24.

Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy.

Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL.

Urol Oncol. 2017 Sep;35(9):542.e25-542.e32. doi: 10.1016/j.urolonc.2017.04.018. Epub 2017 May 19.

PMID:
28533151
25.

Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.

Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng FY, Klein EA.

Eur Urol. 2017 Nov;72(5):845-852. doi: 10.1016/j.eururo.2017.05.009. Epub 2017 May 19.

26.

A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.

Sanford NN, Catalano PJ, Enzinger PC, King BL, Bueno R, Martin NE, Hong TS, Wo JY, Mamon HJ.

Dis Esophagus. 2017 Jul 1;30(7):1-8. doi: 10.1093/dote/dox025.

PMID:
28475728
27.

National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.

Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE, Feng FY, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):338-343. doi: 10.1016/j.ijrobp.2017.02.020. Epub 2017 Feb 21.

PMID:
28463152
28.

Radiation Oncology Health Information Technology: Is It Working For or Against Us?

Pan HY, Mazur LM, Martin NE, Mayo CS, Santanam L, Pawlicki T, Marks LB, Smith BD.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):259-262. doi: 10.1016/j.ijrobp.2017.02.018. No abstract available.

PMID:
28463141
29.

Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer.

Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF 3rd, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL.

Clin Genitourin Cancer. 2017 Oct;15(5):563-569.e3. doi: 10.1016/j.clgc.2016.10.011. Epub 2016 Oct 28.

PMID:
28462857
30.

Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL.

Ann Oncol. 2017 May 1;28(5):1098-1104. doi: 10.1093/annonc/mdx041.

PMID:
28453693
31.

Implementing patient-reported outcome surveys as part of routine care: lessons from an academic radiation oncology department.

Rotenstein LS, Agarwal A, O'Neil K, Kelly A, Keaty M, Whitehouse C, Kalinowski B, Orio PF 3rd, Wagle N, Martin NE.

J Am Med Inform Assoc. 2017 Sep 1;24(5):964-968. doi: 10.1093/jamia/ocx009.

PMID:
28339771
32.

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer.

Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):186-192. doi: 10.1038/pcan.2016.58. Epub 2017 Jan 24.

33.

The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.

Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA.

Cancer Metab. 2016 Dec 7;4:22. doi: 10.1186/s40170-016-0161-9. eCollection 2016.

34.

Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.

Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs CS, Martin NE, Getz G, Carter S, Mamon HJ, Hornick JL, Van Allen EM, D'Andrea AD.

Clin Cancer Res. 2017 Jun 15;23(12):3214-3222. doi: 10.1158/1078-0432.CCR-16-2017. Epub 2016 Nov 16.

35.

National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL.

Cancer. 2016 Nov 15;122(21):3371-3377. doi: 10.1002/cncr.30205. Epub 2016 Jul 19.

36.

Clinical implementation of a novel applicator in high-dose-rate brachytherapy treatment of esophageal cancer.

Buzurovic IM, Hansen JL, Bhagwat MS, O'Farrell DA, Friesen S, Harris TC, Damato AL, Cormack RA, Martin NE, Devlin PM.

J Contemp Brachytherapy. 2016 Aug;8(4):319-25. doi: 10.5114/jcb.2016.61933. Epub 2016 Aug 23.

37.

Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.

Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL.

Brachytherapy. 2016 Nov - Dec;15(6):695-700. doi: 10.1016/j.brachy.2016.07.001. Epub 2016 Aug 12.

PMID:
27528590
38.

Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects.

Stalker D, Reid S, Ramaiya A, Wisemandle WA, Martin NE.

Clin Ther. 2016 Aug;38(8):1778-88. doi: 10.1016/j.clinthera.2016.06.010. Epub 2016 Jul 26.

PMID:
27473384
39.

Unfavorable Intermediate-Risk Prostate Cancer and the Odds of Upgrading to Gleason 8 or Higher at Prostatectomy.

Martin NE, Chen MH, Zhang D, Richie JP, D'Amico AV.

Clin Genitourin Cancer. 2017 Apr;15(2):237-241. doi: 10.1016/j.clgc.2016.06.001. Epub 2016 Jun 16.

PMID:
27426058
40.

Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer.

Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL.

J Natl Compr Canc Netw. 2016 Apr;14(4):421-8.

PMID:
27059190
41.

Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.

Muralidhar V, Xiang M, Orio PF 3rd, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL.

J Contemp Brachytherapy. 2016 Feb;8(1):1-6. doi: 10.5114/jcb.2016.58080. Epub 2016 Feb 29.

42.

New developments in prostate cancer biomarkers.

Martin NE.

Curr Opin Oncol. 2016 May;28(3):248-52. doi: 10.1097/CCO.0000000000000279. Review.

PMID:
26974844
43.

Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.

Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):683-90. doi: 10.1016/j.ijrobp.2015.12.008. Epub 2015 Dec 14.

44.

National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study.

Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF 3rd, Nguyen PL.

Cancer. 2016 May 15;122(10):1505-12. doi: 10.1002/cncr.29960. Epub 2016 Mar 11.

45.

Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing.

Thaker NG, Pugh TJ, Mahmood U, Choi S, Spinks TE, Martin NE, Sio TT, Kudchadker RJ, Kaplan RS, Kuban DA, Swanson DA, Orio PF, Zelefsky MJ, Cox BW, Potters L, Buchholz TA, Feeley TW, Frank SJ.

Brachytherapy. 2016 May-Jun;15(3):274-282. doi: 10.1016/j.brachy.2016.01.003. Epub 2016 Feb 23.

46.

Analysis of After-Hours Patient Telephone Calls in Two Academic Radiation Oncology Departments: An Opportunity for Improvement in Patient Safety and Quality of Care.

Warren LE, Kim MB, Martin NE, Shih HA.

J Oncol Pract. 2016 Apr;12(4):e487-94. doi: 10.1200/JOP.2015.007583. Epub 2016 Feb 23.

PMID:
26907449
48.

Of the Community.

Martin NE.

Midwifery Today Int Midwife. Winter 2016;(120):25-7. No abstract available.

PMID:
29912504
49.

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.

Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):828-35. doi: 10.1016/j.ijrobp.2015.07.2281. Epub 2015 Jul 29.

50.

Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.

Falchook AD, Martin NE, Basak R, Smith AB, Milowsky MI, Chen RC.

Urol Oncol. 2016 Mar;34(3):119.e19-26. doi: 10.1016/j.urolonc.2015.09.014. Epub 2015 Oct 29.

PMID:
26526383

Supplemental Content

Loading ...
Support Center